on Biotricity, Inc. (NASDAQ:BTCY)
Biotricity Projects Significant Improvements in Year-End Financial Results
REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ: BTCY), a Technology-as-a-Service (TaaS) company specializing in healthcare solutions, has provided year-end financial guidance. The company forecasts meeting analyst revenue targets and surpassing loss and margin goals.
Biotricity anticipates revenue growth exceeding 24% year-over-year (YoY). Additionally, the company expects a decrease in Loss from Operations by over 40% YoY and an improvement in margins by over 10% YoY.
Dr. Waqaas Al-Siddiq, Founder and CEO, highlighted that these achievements demonstrate sustained growth and efficiency, positioning Biotricity on a path to profitability and cashflow breakeven. He emphasized the unique combination of growth, reduction in losses, and margin improvement experienced by the company.
Biotricity's success is credited to its robust business model, high adoption rates of its solutions, and operational efficiency within the cardiac market. The company continues to lead the market with its TaaS model, known for strong margins and customer retention.
R. P.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biotricity, Inc. news